Skip to main content
SpringerLink
Log in

Conventional and Moderately Hypofractionated Radiation Therapy for Prostate Cancer

  • Chapter
  • First Online:
Radiation Therapy for Genitourinary Malignancies

Part of the book series: Practical Guides in Radiation Oncology ((PGRO))

  • 640 Accesses

Abstract

External beam radiation therapy (EBRT) is a common treatment modality for localized prostate cancer and may be used alone or in conjunction with other treatment modalities. In this chapter, we review conventionally fractionated and hypofractionated treatment schedules, appropriate patient selection considerations, treatment planning, patient follow-up, outcomes of treatment, and side effect management.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Al-Mamgani A, van Putten WLJ, Heemsbergen WD, van Leenders GJLH, Slot A, Dielwart MFH et al (2008) Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 72(4):980–988

    Article  PubMed  Google Scholar 

  2. Pollack A, Zagars G, Starkschall G, Antolak J, Lee JJ, Huang E et al (2002) Prostate cancer radiation dose response: results of the MD Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53(5):1097–1105. http://www.ncbi.nlm.nih.gov/pubmed/12654464

    Article  PubMed  Google Scholar 

  3. Dearnaley DP, Hall E, Lawrence D, Huddart RA, Eeles R, Nutting CM et al (2005) Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer 92(3):488–498

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Peeters S, Heemsbergen W, Koper P, van Putten W, Slot A, Dielwart M et al (2006) Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24(13):1990–1996

    Article  PubMed  Google Scholar 

  5. Benjamin LC, Tree AC, Dearnaley DP (2017) The role of hypofractionated radiotherapy in prostate cancer. Curr Oncol Rep 19(4):30

    Article  PubMed  PubMed Central  Google Scholar 

  6. Morgan SC, Hoffman K, Loblaw DA, Buyyounouski MK, Patton C, Barocas D et al (2018) Hypofractionated radiation therapy for localized prostate cancer: an ASTRO, ASCO, and AUA evidence-based guideline. Pract Radiat Oncol 36(34):3411–3430

    CAS  Google Scholar 

  7. Lee WR, Dignam JJ, Amin MB, Bruner DW, Low D, Swanson GP et al (2016) Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol 34(20):2325–2332

    Article  PubMed  PubMed Central  Google Scholar 

  8. Catton CN, Lukka H, Gu CS, Martin JM, Supiot S, Chung PWM et al (2017) Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol 35(17):1884–1890

    Article  CAS  PubMed  Google Scholar 

  9. Wilson JM, Dearnaley DP, Syndikus I, Khoo V, Birtle A, Bloomfield D et al (2018) The efficacy and safety of conventional and hypofractionated high-dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. Int J Radiat Oncol Biol Phys 100(5):1179–1189. https://doi.org/10.1016/j.ijrobp.2018.01.016

    Article  PubMed  PubMed Central  Google Scholar 

  10. Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D et al (2016) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 17(8):1047–1060. https://doi.org/10.1016/S1470-2045(16)30102-4

    Article  PubMed  PubMed Central  Google Scholar 

  11. Wilkins A, Mossop H, Syndikus I, Khoo V, Bloomfield D, Parker C et al (2015) Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 16(16):1605–1616. https://doi.org/10.1016/S1470-2045(15)00280-6

    Article  PubMed  PubMed Central  Google Scholar 

  12. Dearnaley D, Syndikus I, Sumo G, Bidmead M, Bloomfield D, Clark C et al (2012) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol 13(1):43–54

    Article  PubMed  Google Scholar 

  13. Incrocci L, Wortel RC, Alemayehu WG, Aluwini S, Schimmel E, Krol S et al (2016) Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 17:1061–1069. https://doi.org/10.1016/S1470-2045(16)30070-5

    Article  PubMed  Google Scholar 

  14. Aluwini S, Pos F, Schimmel E, Krol S, van der Toorn PP, de Jager H et al (2016) Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial. Lancet Oncol 17(4):464–474. https://doi.org/10.1016/S1470-2045(15)00567-7

    Article  PubMed  Google Scholar 

  15. Aluwini S, Incrocci L, Wortel RC, Alemayehu WG, Schimmel E, Krol S et al (2015) Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial. Lancet Oncol 16:274–283. https://doi.org/10.1016/S1470-2045(14)70482-6

    Article  PubMed  Google Scholar 

  16. Chen RC, Bryan Rumble R, Andrew Loblaw D, Finelli A, Ehdaie B, Cooperberg MR et al (2016) Active surveillance for the management of localized prostate cancer (Cancer Care Ontario guideline): American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol 34(18):2182–2190

    Article  PubMed  Google Scholar 

  17. Wu R, Woodford H, Capp A, Hunter P, Cowin G, Tai KH et al (2015) A prospective study of nomogram-based adaptation of prostate radiotherapy target volumes. Radiat Oncol 10(1):1–9. https://doi.org/10.1186/s13014-015-0545-y

    Article  CAS  Google Scholar 

  18. Morris WJ, Tyldesley S, Rodda S, Halperin R, Pai H, McKenzie M et al (2017) Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 98(2):275–285. https://doi.org/10.1016/j.ijrobp.2016.11.026

    Article  PubMed  Google Scholar 

  19. Rodda S, Tyldesley S, Morris J, Keyes M, Halperin R, PAi H et al (2017) ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing low-dose-rate brachytherapy boost with dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 98(2):286–295. https://doi.org/10.1016/j.ijrobp.2017.01.008

    Article  PubMed  Google Scholar 

  20. Rodda S, Morris WJ, Hamm J, Duncan G (2017) ASCENDE-RT: an analysis of health-related quality of life for a randomized trial comparing low-dose-rate brachytherapy boost with dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 98(3):581–589. https://doi.org/10.1016/j.ijrobp.2017.02.027

    Article  PubMed  Google Scholar 

  21. Roach M, Winter K, Michalski JM, Cox JD, Purdy JA, Bosch W et al (2004) Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: findings from a prospective, multi-institutional, phase I/II dose-escalation study. Int J Radiat Oncol Biol Phys 60(5):1351–1356

    Article  PubMed  Google Scholar 

  22. Zelefsky MJ, Kollmeier M, Cox B, Fidaleo A, Sperling D, Pei X et al (2012) Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 84(1):125–129. https://doi.org/10.1016/j.ijrobp.2011.11.047

    Article  PubMed  Google Scholar 

  23. Aizer AA, Yu JB, Colberg JW, McKeon AM, Decker RH, Peschel RE (2009) Radical prostatectomy vs. intensity-modulated radiation therapy in the management of localized prostate adenocarcinoma. Radiother Oncol 93(2):185–191. https://doi.org/10.1016/j.radonc.2009.09.001

    Article  PubMed  Google Scholar 

  24. Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P et al (2016) 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 375(15):1415–1424. https://doi.org/10.1056/NEJMoa1606220

    Article  PubMed  Google Scholar 

  25. Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E et al (2016) Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 15:1425–1437

    Article  Google Scholar 

  26. Roach M, Hanks G, Thames H, Schellhammer P, Shipley WU, Sokol GH et al (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65(4):965–974

    Article  PubMed  Google Scholar 

  27. NCCN (2018) Prostate cancer NCCN evidence blocks

    Google Scholar 

  28. Chao M, Ho H, Chan Y, Tan A, Pham T, Bolton D et al (2018) Prospective analysis of hydrogel spacer for patients with prostate cancer undergoing radiotherapy. BJU Int 122(3):427–433

    Article  CAS  PubMed  Google Scholar 

  29. Zaorsky NG, Showalter TN, Ezzell GA, Nguyen PL, Assimos DG, D’Amico AV et al (2017) ACR Appropriateness Criteria for external beam radiation therapy treatment planning for clinically localized prostate cancer, part I of II. Adv Radiat Oncol 2:62–84. https://doi.org/10.1016/j.adro.2016.10.002

    Article  PubMed  Google Scholar 

  30. Mariados N, Sylvester J, Shah D, Karsh L, Hudes R, Beyer D et al (2015) Hydrogel spacer prospective multicenter randomized controlled pivotal trial: dosimetric and clinical effects of perirectal spacer application in men undergoing prostate image guided intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys 92(5):971–977. https://doi.org/10.1016/j.ijrobp.2015.04.030

    Article  PubMed  Google Scholar 

  31. Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A et al (2008) Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 70(4):1124–1129

    Article  PubMed  Google Scholar 

  32. Oscarsson N, Müller B, Rosén A, Lodding P, Mölne J, Giglio D et al (2019) Radiation-induced cystitis treated with hyperbaric oxygen therapy (RICH-ART): a randomised, controlled, phase 2–3 trial. Lancet Oncol 20(11):1602–1614

    Article  PubMed  Google Scholar 

  33. Dall’Era MA, Hampson NB, Hsi RA, Madsen B, Corman JM (2006) Hyperbaric oxygen therapy for radiation induced proctopathy in men treated for prostate cancer. J Urol 176(July):87–90

    Article  PubMed  Google Scholar 

  34. Jin T, Song T, Deng S, Wang K (2014) Radiation-induced secondary malignancy in prostate cancer: a systematic review and meta-analysis. Urol Int 93(3):279–288

    Article  CAS  PubMed  Google Scholar 

  35. Nieder AM, Porter MP, Soloway MS (2008) Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study. J Urol 180(5):2005–2010

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, IN, USA

    Ethan M. Steele, Todd R. Mereniuk & Jordan A. Holmes

  2. Department of Radiation Oncology, Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN, USA

    Jordan A. Holmes

Authors
  1. Ethan M. Steele
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Todd R. Mereniuk
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jordan A. Holmes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jordan A. Holmes .

Editor information

Editors and Affiliations

  1. Department of Radiation Oncology, Loyola University Chicago, Maywood, IL, USA

    Abhishek A. Solanki

  2. Department of Radiation Oncology, University of Kansas Medical Center, Kansas City, KS, USA

    Ronald C. Chen

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Steele, E.M., Mereniuk, T.R., Holmes, J.A. (2021). Conventional and Moderately Hypofractionated Radiation Therapy for Prostate Cancer. In: Solanki, A.A., Chen, R.C. (eds) Radiation Therapy for Genitourinary Malignancies . Practical Guides in Radiation Oncology. Springer, Cham. https://doi.org/10.1007/978-3-030-65137-4_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-65137-4_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-65136-7

  • Online ISBN: 978-3-030-65137-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation